Ansa Biotechnologies
YC W20Emeryville, US · Founded 2018 · 72 employees · 5 known investors
Ansa Biotechnologies develops an enzyme-based process to manufacture DNA, offering an alternative to the established chemical synthesis methods used in the industry. The technology targets research and industrial applications across therapeutics, diagnostics, and biological production.
Founders & leadership· Y Combinator alumni (W20)
Investors · 5
In the news
- Ansa Biotechnologies raises $45 million to expand DNA synthesis | Drug Discovery Newsdrugdiscoverynews.com · 2025
- Ansa snares $54.4M in series B financing to boost its DNA synthesis platformfiercepharma.com · 2025
- Ansa Biotechnologies Raises $54.4M in Series B Financingfinsmes.com · 2025
- Ansa Biotechnologies Secures $54.4 Million in Series B Financing to Redefine How Scientists Access Synthetic DNA with Industry’s First Guaranteed On-Time Servicefinance.yahoo.com · 2025
- Top Life Sciences Startups to Watch in 2023 | BioSpacebiospace.com · 2023
- DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visionsgenengnews.com · 2022
- Ansa Biotechnologies ties up $68M for DNA synthesis platformfiercebiotech.com · 2022
- Ansa Biotechnologies - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2021